If the continuous insurance payment 12 months or more, the cumulative maximum payment limit of the annual overall fund is 460,000 yuan. 12 months to continue to participate in the insurance payment, the cumulative maximum payment limit of the annual overall fund is 280,000 yuan. In addition, the amount of individual medical insurance to maintain overall planning is 2000 yuan per year, that is, when individuals enjoy medical insurance benefits every year, the upper limit of the part paid by the medical insurance fund is deposited in the individual medical insurance overall planning account, which does not exceed 2000 yuan.
The application steps of medical insurance for serious illness are as follows:
1, apply for registration. The insured brings the original and photocopy of his ID card to the business hall of the insurance company, selects the medical insurance products suitable for him, and then fills in the insurance application form;
2. Choose payment methods, including one-time payment, annual payment and monthly payment.
3. Handle or submit a current bank card for paying premiums or receiving insurance benefits in the future;
4. Read and sign the insurance contract. The insured shall read the terms of the medical insurance contract for serious illness in detail and sign it after confirming that there is no objection;
5. Pay the premium. After signing the insurance contract, the insured must pay the down payment. If it is paid annually, the corresponding premium will be paid every year.
To sum up, the annual quota of medical insurance pooling account will be affected by many factors, including region, medical insurance type and payment time. In order to obtain accurate quota information, it is recommended to consult the local medical insurance department or relevant institutions.
legal ground
People's Republic of China (PRC) social insurance law
Article 29
The medical expenses of the insured shall be paid by the basic medical insurance fund, and shall be directly settled by social insurance agencies, medical institutions and pharmaceutical business units.